HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kratz, F. Articles by Messori, L. Search for Related Content PubMed PubMed Citation Articles by Kratz, F. Articles by Messori, L. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 269, Issue 4, 2581-2588, 01, 1994

The binding properties of two antitumor ruthenium(III) complexes to apotransferrin

F Kratz, M Hartmann, B Keppler and L Messori
Department of Chemistry, University of Florence, Italy.

The interaction of two ruthenium(III) complexes exhibiting high anticancer activity, namely trans- indazolium(bisindazole)tetrachlororuthenate(III) (ru-ind) and trans- imidazolium(bisimidazole)tetrachlororuthenate(III) (ru-im), with human serum apotransferrin has been investigated through spectroscopic and chromatographic techniques with the ultimate goal of preparing adducts with good selectivity for cancer cells. Whereas the binding of ru-im to human serum apotransferrin takes several hours, ru-ind, the less toxic complex, gives rise to a well defined 2:1 complex within a few minutes. We have ascertained that ru-ind binding occurs around the iron binding sites; binding does not occur in the absence of bicarbonate, and this anion dictates the kinetic and mechanistic characteristics of protein binding of ru-ind. The two ruthenium(III) complexes do not behave as iron(III) complexes, e.g. Fe(EDTA) or Fe(nitrilotriacetate), which lose their respective ligands when binding apotransferrin, but the N- heterocycles remain attached to the metal in the protein-bound species. Reversion of binding is obtained by acidification in the presence of chelators such as citrate or ATP. In comparison with cisplatin and its deactivation by serum proteins, our results indicate that other metal complexes such as ru-ind could use transferrin as a drug delivery system. Furthermore, the rapid protein binding of ru-ind seems to be related to a lower toxicity while still exhibiting high antitumor activity.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. L. Vavere and M. J. Welch Preparation, Biodistribution, and Small Animal PET of 45Ti-Transferrin J. Nucl. Med., April 1, 2005; 46(4): 683 - 690. [Abstract] [Full Text] [PDF]

				P. Heffeter, M. Pongratz, E. Steiner, P. Chiba, M. A. Jakupec, L. Elbling, B. Marian, W. Korner, F. Sevelda, M. Micksche, et al. Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A) J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 281 - 289. [Abstract] [Full Text] [PDF]

				Z. M. Qian, H. Li, H. Sun, and K. Ho Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway Pharmacol. Rev., December 1, 2002; 54(4): 561 - 587. [Abstract] [Full Text] [PDF]

				H. Li, P. J. Sadler, and H. Sun Unexpectedly Strong Binding of a Large Metal Ion (Bi[IMAGE]) to Human Serum Transferrin J. Biol. Chem., April 19, 1996; 271(16): 9483 - 9489. [Abstract] [Full Text] [PDF]

				H. Sun, H. Li, A. B. Mason, R. C. Woodworth, and P. J. Sadler Competitive Binding of Bismuth to Transferrin and Albumin in Aqueous Solution and in Blood Plasma J. Biol. Chem., March 16, 2001; 276(12): 8829 - 8835. [Abstract] [Full Text] [PDF]